Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for MK-3475

3 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCHN14108

04/09/2015

A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab

Treatment

VICCUROP1468

12/04/2014

A Phase 1b, Open Label, Dose Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination with MK-3475 in Patients with Advanced Renal Cell Cancer

Treatment

VICCMD13112

05/19/2014

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors